“The findings demonstrate PromarkerD’s appeal to clinicians and payors in the management of diabetes. This study shows PromarkerD offers a cost-effective, personalised approach to improving patient outcomes. It allows earlier targeted treatment of those patients at highest risk of diabetic kidney disease, while avoiding unnecessary interventions for people at low risk.“
“Results from the new study add to a previous economic health benefit study that demonstrated the potential cost savings to the US healthcare system if PromarkerD was adopted.
The health benefit study, conducted by independent consultant Boston Healthcare Associates, modelled the budget impact of PromarkerD against existing care standards in the US. It concluded PromarkerD testing could lead to a whopping US$384 billion savings to the US healthcare system over a decade.“